Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Med 2021 | Tabelecleucel in EBV-associated PTLD

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes the Phase III MATCH (NCT03392142) and ALLELE (NCT03394365) clinical trials investigating the efficacy and safety of tabelecleucel, an allogeneic EBV-specific T cell therapy, for the treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) following hematopoietic cell or solid organ transplantation. Results have demonstrated an objective response rate of 50% and a two-year overall survival rate of 80%, which is promising given the median life expectancy in this patient group following first-line therapy is 2-3 months. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.


Pascal Touchon is the President & CEO of Atara Biotherapeutics, San Francisco, CA.